— Know what they know.
Not Investment Advice
Also trades as: HLN.L (LSE) · $vol 114M · HLN (NYSE) · $vol 85M

HLNCF OTC

Haleon plc
1W: -0.6% 1M: +7.4% 3M: +2.9% YTD: +2.7% 1Y: +1.0% 3Y: +17.7%
$4.92
-0.07 (-1.31%)
 
Weekly Expected Move ±5.3%
$4 $5 $5 $5 $5
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Alpha Radar Buy · Power 75 · $43.3B mcap · 8.39B float · 0.0003% daily turnover · Short 65% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$43.3B
52W Range4.15-5.75
Volume412
Avg Volume26,401
Beta0.24
Dividend$0.10
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOBrian James McNamara
Employees24,561
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2022-07-28
Websitehaleon.com
Building 5
Weybridge, SU KT13 0NY
GB
44 1932 822000
About Haleon plc

Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Its business activities cover extensive regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various solutions such as oral hygiene products, pain management remedies, respiratory care items, digestive health aids, and a selection of vitamins, minerals, and supplements. Its notable brand collection features Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially named DRVW 2022 plc before officially rebranding to Haleon plc in February 2022. Its main office is situated in Brentford, United Kingdom.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms